Gene expression test maker Agendia will ramp up its U.S. marketing efforts after gaining expanded FDA clearance and Medicare coverage for its flagship MammaPrint breast cancer recurrence test. On Dec. 17, Agendia announced it had received FDA clearance to test patients of all ages; previously, the test was cleared for use in patients aged 61 and younger only.And in November, the assay gained Medicare reimbursement coding guidelines under a local coverage decision from California Medicare administrator...